Denosumab: “better” than zoledronate?

A media release issued yesterday by Amgen claims that denosumab “demonstrated superiority” over zoledronate (Zometa) in a randomized, multi-center, Phase III clinical trial in prostate cancer patients with bone metastases. … READ MORE …

Is denosumab “better” than Zometa at preventing skeletal events?

Amgen, the developer of denosumab (also known as RANK-L) has released data today from a head-to-head trial of their drug vs. zoledronate (Zometa) in the management of patients with advanced breast cancer and bone metastases. … READ MORE …

The weekend prostate cancer news: Saturday, January 31, 2009

Items covered in this weekend news report include:

  • Acrylamide exposure as a potential risk for prostate cancer
  • The relative merits of three standard first-line therapies in intermediate risk prostate cancer
  • Estramustine + etopside in hormone-refractory prostate cancer (HRPC)
  • Bone turnover markers and risk for skeletal-related events in patients receiving zoledronic acid … READ MORE …